Thursday, 30 June 2016

Blood and Organ Bank Market Segment Forecast up to 2023

Blood transfusion and Organ transplant is done to save the life of an individual or to improve patient’s health. Blood bank is an institute from where blood is, stored entirely or as its components (plasma, blood cells and platelets) which is then transfused to the needy patients suffering with deficiency of blood or blood components. Organ Banks are banks which recover, process, storage and distributing an organ as well as body tissue and bone for transplantation. A single organ and tissue donor can save up to 40-50 patients’ lives which marks the importance of blood and organ banks.
Every year million cases either undergo transfusion of blood, blood components, plasma derivatives, and transplantation of organs. According to the World Health Organization (WHO), out of 108 million blood donations done globally, 50% of the blood donations happen in high income countries. More than 65% of blood transfusions in low income countries are given to children below five years of age while the scenario is reverse in high income countries where transfusion is done for elderly patients (age 65 years and above). According to another report by the WHO, voluntary unpaid blood donations have increased tremendously in low- and middle-income nations. From 2004 to 2012, more than 8.6 million blood donations that came from voluntary unpaid donors has increased in 162 countries. Among these countries, there were 73 nations which.
The blood and organ market is segmented on the basis of the following: Products (Blood products which include whole blood, Red blood cells, Platelets, Granulocytes, Fresh frozen plasma, Albumin, Immunoglobulin, Antithrombin III and Protein C concentrate and others (Factor VIIa, Factor VIII Fraction, Dried factor IX fraction, Factor XIII dried) and under Organs include (Kidney, liver, heart, pancreas and cornea).The end users include either the Public Hospitals or the Private Hospitals.
On the basis of geography, the global the blood and organ market can be segmented into North America , Europe, Asia Pacific, Latin America, and Middle East and Africa. North America has been a leading region in the market owing to high demand for organ transplant. Annually, more than 120,000 Americans need a new organ.
The blood and organ bank industry has grown healthily in past decades and is expected to continue its growth trajectory during the forecast period from 2015 to 2023. According to the Organ Procurement and Transplantation Network (OPTN), more than 1 million patients are on waiting list for organ transplant. As the number of organ donors is increasing, an increase in transplant procedures is bound to happen this will expand the global market for blood and organ bank market. Moreover, the government efforts for creating awareness for blood donation and restoring donors’ and the patient’s confidence in blood transfusion services has also up stretched the demand for these systems. Rising incidences of accidents are propelling the market for blood and organ banks because in such cases there is high probability of demand for blood or organ. Increasing healthcare insurance coverage, greater improvement in post-transplant outcomes are among other factors that help drive the market growth.
Some of the market players in this industry segment are The American Red Cross, Blood Systems, Musculoskeletal Transplant Foundation, Inc., New York Blood Center, New England Organ Bank, The Living Bank, NOTTO and 21st Century Medicine.

Healthy Growth Predicted for Gene Therapy Market

Gene therapy is a burgeoning market within the pharmaceutical industry and is teeming with new opportunities. Transparency Market Research’s latest report titled ‘Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019’ provides a comprehensive analysis of one of the most critical medical fields. The market analyses and estimates contained in this report are of special significance to pharmaceutical companies, educational institutes, marketing professionals, and entrepreneurs venturing into the gene therapy market.
Key highlights of this report include: market growth drivers and restraints, current trends and emerging opportunities, value chain analysis, estimates and forecasts of segment-wise growth, as well as a profiles of all leading players in the gene therapy market over the period of forecast. The report also leverages the Porter’s five forces model to analyze the future threats and bargaining power of stakeholders such as suppliers, consumers and manufacturers. Other macro and micro factors that are essential for the sustenance of existing market players are encompassed in this report.
Market overview
Gene therapy entails the use of DNA in the capacity of a drug, for the prevention or treatment of diseases. This is one of the most defining developments in the pharmaceutical industry, and is expected to have far-reaching implications on life-threatening diseases in the future. Some diseases that can be potentially treated using gene therapy include: cancer, HIV, and cystic fibrosis. It is anticipated that the clinical trial and biotechnology industry will largely benefit from gene therapy in the long run. And, it is possible that gene therapy could provide a cure for diseases that are regarded as being incurable today.
Currently, the concept of gene therapy is being validated by numerous pharmaceutical companies using clinical data, and there is a growing interest among venture capitalists to explore the commercial potential of gene therapy. However, the growth of the gene therapy market is largely dependent on the regulatory environment, and on approvals from industry bodies. Currently, most gene therapy products are still in the clinical trials phase II and phase III, of which a majority focuses on the treatment of cancer and cardiovascular diseases. The growing popularity of DNA vaccines has positively impacted the growth of this market, and there is a high possibility of gene therapy being practiced in clinics in the next few years, as encouraging results are emerging from the phase II/III trials.
This report profiles key players such as: AnGes MG, Transgene, Urigen Pharmaceuticals, GenVec, Vical, BioSante Pharmaceuticals, Oxford BioMedica, and Genzyme Corporation.

Government Initiatives to Augment Growth of Global Healthcare IT Outsourcing Market

Healthcare IT outsourcing deals with the outsourcing of several IT functions to a third party in order to maintain and manage technology-related operations. The healthcare sector generates vast amounts of data, due to which it needs assistance for tracking the data electronically for billing codes, patient care, and maintaining medical records. As a result, a strong IT infrastructure, solutions, and devices are required to manage the valuable data. However, in the absence of necessary skills and IT-domain expertise, the maintenance of data becomes a crucial task for the healthcare sector. The outsourcing of several IT services helps in allowing healthcare providers to improve their service quality.
As per a research study by Transparency Market Research (TMR), the global market for healthcare IT outsourcing is projected to reach US$61.28 bn by the end of 2023. This market is expected to exhibit a 6.70% CAGR between 2015 and 2023.
In this blog, TMR provides answers to several queries concerning the major opportunities and growth prospects in the global healthcare IT outsourcing market.
What are the primary reasons for IT outsourcing in the healthcare sector?
Nowadays, several healthcare organizations are investing enormously in IT outsourcing in order to enhance their focus on their core services and reduce management costs. Outsourcing also helps in gaining access to world-class products and services, which reduces operational costs. It takes care of several components such as financial data management, patient data management, healthcare data analytics, asset management, and several other administrative services. Moreover, the adoption of IT outsourcing helps in dealing with rising concerns related to data security and consolidates the overall healthcare system.
What are the major developments in the global healthcare IT outsourcing market?
Governments are encouraging healthcare reforms such as International Statistical Classification of Diseases and Related Health Problems (ICD-10) norms, Affordable Care Act (ACA), Health Insurance Exchange (HIX), and Medicare, which have led to increased adoption of IT outsourcing services in the healthcare sector. In addition, the leading players including Accenture Plc., Infosys Limited, McKesson Corporation, IBM Corporation, Allscripts Healthcare Solutions, Inc., and Cognizant Technology Solutions are making continuous efforts to offer advanced IT services to the healthcare sector. For instance, Cognizant has come together with Orion health to develop a cloud platform to allow new levels of payer, provider, and consumer collaboration.
Get a Free Sample Report:
What are the potential growth opportunities for the major players in global healthcare IT outsourcing market?
Healthcare infrastructure has been developing across the globe resulting in high demand for cost-effective IT services. In addition, the booming medical tourism in developing economies has created several opportunities for the major players operating in the global healthcare IT outsourcing market. The growing government interventions to provide the consumers with technology-driven and cost-efficient healthcare services are further expected to boost the demand for healthcare IT outsourcing services in the next few years. Furthermore, the increasing healthcare expenditure and growing patient population worldwide pushes the requirement to outsource IT solutions for enhanced healthcare management.

Upcoming Patent Expirations to Hamper Growth of Global Antibacterial Drugs Market; Market to Exhibit 1.30% CAGR 2015-2023

capsules-385949_1280A new market research study, titled “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” has been published by Transparency Market Research. As per the study, in 2014, the global antibacterial drugs market was worth US$43.9 bn. The market is projected to exhibit a 1.30% CAGR between 2015 and 2023, declining in value to touch US$38.9 bn by the end of 2023.
An antibacterial drug is an antimicrobial agent that interferes with the reproduction and growth of bacteria. The growth of this bacteria can cause severe infections in animals and humans. The administration of antibacterial drugs helps in inhibiting the growth of the bacteria or completely killing it. At present, several antibacterial drugs in different formulations are available and are widely used for treating tuberculosis, legionellosis, like pneumonia, diarrhea, diphtheria, tetanus, and other diseases. Some of the prominent consumers of the global antibacterial drugs market are private clinics, hospitals, patients, and physicians.
The growing prevalence of infections and other diseases across the globe and increasing government support for research and development activities are some of the key drivers of the global antibacterial drugs market. However, the upcoming patent expirations and growth in drug-resistant species are projected to curtail the growth of the market in the coming years. The decline in the markets valuations will primarily be attributable to this negative factor.
In 2014, the β-lactams segment accounted for a 58% share in the global antibacterial drugs market and is estimated to be in the topmost position in the next few years. In the same year, the quinolones segment accounted for a 17% share in the global market and is expected to exhibit negative growth rate in the forecast period. Furthermore, the miscellaneous antibacterial segment is projected to witness significant growth owing to the growing demand for therapies against bacterial infections and rising geriatric population.
The strong pipeline in the global antibacterial drugs market includes RHB-105, Eravacycline, Ozenoxacin, Arikace, Carbavance (meropenem/RPX7009), Surotomycin (MK-4261), SYM-1219, Solithromycin (CEM-101), Plazomycin, Ciprofloxacin/Fluocinolone Acetonide, SPL7013, Actoxumab/Aezlotoxumab, (MK-3415A), Omadacycline (PTK-0796), Zempia (E-101), Cadazolid, Delafloxacin, and Delamanid. The major players are making constant efforts to commercialize these drugs, which is estimated to propel the global antibacterial drugs market in the near future.
At present, Asia Pacific accounts for the largest share in the global antibacterial drugs market and is projected to grow at a fast pace throughout the forecast period. The rapid growth of this region can be attributed to the strong presence of generic pharmaceutical ingredients and generic manufacturers, a growing geriatric population, and expanding population. In addition, the growing incidence of several bacterial infections including MRSA and TB, developing healthcare infrastructure, and rising purchasing power of consumers are some of the other factors anticipated to drive global antibacterial drugs market in the coming years.
Asia Pacific is followed by North America and Europe. These regions are expected to witness sluggish growth throughout the forecast period. The slow-paced growth of the North America and Europe antibacterial drugs markets can be attributed to the strict regulatory requirements, market maturity, and shortened product lifecycle.
The prominent players engaged in the global antibacterial drugs market include Bayer AG, Forest Laboratories, Inc., Allergan plc, Johnson & Johnson, AstraZeneca plc, Sanofi, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Eli Lilly & Co., Novartis AG, Merck & Co., Inc., and Pfizer, Inc. These players are leading the overall market and witnessing intense competition amongst each other. Among these players, Pfizer, Inc. is considered as a dominant player owing to its significant contribution towards the global antibacterial drugs market.

Tuesday, 28 June 2016

Global Cord Blood Banking Services Market Hampered by Blood Shortage and Restrictive Usage; Market to Reach US$15.23 bn by 2019

Stem cells are capable of producing all the three types of blood cells produced in human body i.e. red blood cells, platelets and white blood cells. Researchers have discovered that stem cells can be used for the treatment of 80 different diseases including thalassemia, sickle cell anemia, leukemia diabetes and cardiac diseases. The major sources for stem cell banking are storing of peripheral blood and bone marrow, umbilical cord blood (UCB) is by far considered as the largest component for hematopoietic stem cells. Donated cord blood has become one of the most reliable sources for stem cells over the last decade and is thus considered as a valuable biological resource. The chances of cord blood sample matching with the patients that is closely in relation to the baby whose sample is to be used are 39% more than the sample obtained from the public banks. Cord blood banking services is a promising and a fast growing segment in the field of next generation stem cell therapy and national cord blood registries are changing perception and look of the industry.
Cord blood can be stored in either of the two ways, banking in private cord blood banks or donating in public cord blood banks. Private cord blood banks collect and store cord blood for the use of baby and close family members only. Collection and storage of the cord blood is charged to the parents of the baby. And secondly the cord blood can be donated to a public bank where the cord blood unit is stored and is publically available for the suitable match. All the charges of storage and maintenance of the cord blood unit obtained from public bank are taken from the patient or patient’s family for whom the unit is going to utilize in transplantation process. Though globally the number of private cord blood banks are more as compared to public banks, number of units stored in public banks are more than units of cord blood banks stored in private banks globally.
The amount of stem cells required for the transplantation process vary depending on person’s weight and age. The major disadvantage of cord blood storing in private cord blood bank is that the single unit of the cord blood contains insufficient amount of stem cells and becomes difficult to treat adults using stem cell transplant. On the other hand, cord blood units stored in public banks is available to any patient matching with the blood unit sample stored in public banks globally. And hence multiple units can be utilized for single patient to meet the requirement of the stem cells in transplantation procedure.
Taking inability of the privately stored cord blood units to meet the requirement of the amount of stem cell into consideration healthcare professionals are focusing on enhancing cord blood inventory in public banks so that demand for the cord blood units can be matched. Gynecologists, pediatricians and obstetricians recommend to store cord blood in private banks only if the family has history of the disease that can be treated using stem cells.
Geographically North America is dominating the global cord blood banking services market followed by Europe. Governments taking initiative to regulate the cord blood banking industry in the country and implementation of hybrid model to reduce the attrition between private cord blood banking and public cord blood banks is driving the growth of cord blood banking services market. Asia-Pacific is lucrative market owing to increased cord blood banking in countries like China and India. Contribution of Asian countries in banking cord blood is expected to increase further as medical tourism industry is booming in this region. Growing awareness about cord blood banking and treatments that can cure blood borne diseases using stem cells in cord blood is increasing. Countries like France, Italy and UAE have banned private banking of the cord blood. Governments of these countries are actively participating in establishing nationwide public banks to enhance the inventory of the cord blood units.

Idiopathic Short Stature Market Trends & Forecast up to 2020

Idiopathic short stature (ISS) refers to children with shorten growth of body where the reason behind the physical condition is unknown. The children with height less than 2 standard deviations (SDs) are categorized in this clinical condition. The group of idiopathic short children includes children with delay of growth and puberty, hereditary short stature, children with subtle cartilage and bone dysplasias. There is no precise medical cause for ISS, whereas some reasons include genetic structure and other orthopedic related complications.
The disease often diagnosed by X-rays of the left wrist or hand along with complete blood count, growth hormone stimulation test, insulin growth factor-1 test and other blood related tests. Though there is ongoing debate about treatment of ISS based on growth hormones but based on the physical and blood test, generally hormonal therapy is recommended by health care professionals In 2003, United States Food and Drug Administration (FDA) approved human growth hormone treatment for children with idiopathic short stature (height below 2.25 SD). According to survey conducted by European Society of Endocrinologist, 94% physicians prefer growth hormone treatment for ISS.
Children with idiopathic short stature can be found in all parts of the world. According to The Endocrine Society based in United States, It is estimated that approximately 60 – 80% of all children across the globe with short stature fit in the category of ISS and therefore total number of people living with ISS will increase accordingly. The above fact stands for demand of various treatment options for ISS globally. The heavy investment in research and development, suitable reimbursement conditions and growing number of patients living with ISS may drive the growth of the market. On the other hand limited awareness and lack of specific treatment may hinder the growth of the overall market.
Currently there are many clinical research projects under study that are focused on developing specific treatment for idiopathic short stature. Merck KGaA has “Saizen” in pipeline for treatment of affected children, Pfizer in collaboration with prestigious Rabin Medical Center exploring the use of biochemical markers of growth with growth hormone treatment, Eli Lilly and Company trying to develop monotherapy of somatropin in pubertal children with ISS, Dong-A Pharmaceutical Co., Ltd. is studying the improvement of height of children by growth hormone therapy.
Idiopathic short stature market can be segmented according to different categories such as regional geography, classification of ISS and categories of drugs available for the treatment. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The treatment market can also be segmented according to categories such as familial ISS and non-familial ISS. According to treatment options available, the market for ISS can be segmented in Growth hormones, genetic therapy and others.
Currently many established players in pharmaceuticals market which are either catering or on the way to develop drugs for idiopathic short stature. Out of these companies, JCR Pharmaceuticals Co., Braasch Biotech LLC, Bolder Biotechnology, Inc., Myungmoon pharmaceutical Co. Ltd, Eli Lilly, Pfizer are leading contributors.

Telepharmacy Market To See Good Times Ahead

Internet of Things in healthcareThe global telepharmacy market has been surging at an exponential rate since the last few years. The market is also poised to exhibit an incredible rate of growth in forthcoming years, as per the findings of Transparency Market Research (TMR). In a new report, titled “Telepharmacy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024” TMR has incorporated various factors and prevailing trends that will shape the trajectory for the global telepharmacy market. The report describes the uses of telepharmacy and its potential roles for pharmacy.
Telepharmacy refers to verifying medication order via telecommunication from a remote location and the delivery of pharmaceutical care. It is designed to help pharmacists ensure better efficiency in patient-care even in remote geographic locations. Telepharmacy is therefore a state-of-the-art technology enabling easy access to quality healthcare, particularly in rural and medically backward areas.
In the majority of healthcare centers located in remote areas, a pharmacist may not be present for the better part of the day to review medications ordered and administered by nurses or other pharmacists. This marks the premise of efficient telepharmacy programs. Not every hospital or healthcare center in a rural community can afford a pharmacist to be continuously present onsite. To mitigate this concern, PipelineRx has tailor-made telepharmacy solutions to cater to the specific needs of hospitals located in backward areas.
PipelineRx’s innovative telepharmacy solutions have been gaining considerable traction globally. These solutions are designed to help hospitals manage their pharmacy operations better and more precisely. The report summarizes the impact of the launch of such new technologies in simplifying the prevalent healthcare operations. Their contribution in fostering better patient care and treatment has been examined in detail. The report also studies the influence of recent technological advancements on the global telepharmacy market.
As with the majority of telehealth solutions, telepharmacy practices have also significantly expanded from healthcare centers located in rural areas to hospitals, military bases, long-term care facilities, naval ships, prisons, and physicians’ offices. Telepharmacy systems are integrated with novel technologies to effortlessly exchange information with telepharmacy systems. This has spurred the deployment of telepharmacy solutions across the world.
The report has pegged PipelineRx as one of the leading platforms globally providing medication management services. The company has recently announced funding worth US$9.1 mn by McKesson Ventures, AMN Healthcare, and Mitsui & Co. (U.S.A.) Inc. PipelineRx is likely to use the investment to strengthen its technology offerings such as integrated delivery network and develop work-flow models for better patient care.
Other companies in the market and profiled in the report include Telepharmacy Solutions Inc., Medication Review, Inc., and North West TelePharmacy Solutions.

Global Osteoporosis Drugs Market to be Propelled by Increasing Prevalence of Osteoporosis

capsules-385949_1280The global osteoporosis drugs market is expected to reach US$8.9 bn by the end of 2020. It was valued at US$8.4 bn in 2013 and is progressing at a CAGR of 1.2% within a forecast period from 2014 to 2020, as stated by TMR analysts. Transparency Market Research is a leading provider of the latest research reports on a number of industries, including the global pharmaceutical industry. The latest report to be added by the market intelligence agency is titled “Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020.” It describes the key factors that will influence this market through the given forecast period.
Osteoporosis is a highly common chronic illness that can range in seriousness from impeding daily life to being life-threatening. When a person suffers from osteoporosis, he or she undergoes a restructure of their bones due to a lack of bone density and mass. As a result, the patient can suffer from serious injuries and bone fractures over time.
The primary driver for the global osteoporosis drugs market, as stated in the report, is the rapidly growing prevalence of the disease across the world. This increase in the patient pool is mostly created by the increasing percentage of the geriatric demographic, which is the most susceptible demographic to osteoporosis.
From the therapeutic side, the global osteoporosis drugs market is being propelled by the recent advancements in drug therapies and the introduction of innovative drugs to the pipeline. Osteoporosis currently cannot be treated by direct surgical procedures, making drug therapies the primary mode of treatment.
The report provides an in-depth analysis of the global osteoporosis drugs market on the basis of several market segments based on the categories of drug class and geography.
In terms of drug class, the report validates the major segments of calcitonin, RANK Ligand inhibitors, SERMs, PTH drugs, bisphosphonates, and others. This category additionally includes an analysis of the global osteoporosis drugs market’s pipeline in order to correctly assess the future prospects in the market.
Bisphosphonates dominated the global osteoporosis drugs market in 2013, with a share of 48.2%. The analysts of the report, however, add that this segment will experience a loss of share during the forecast period, owing to the high severity of side effects linked to it. Furthermore, the decline of the drug with the largest revenue stream – Fosamax – is expected to decelerate the global osteoporosis drugs market even more. Despite the major drop in sales, the bisphosphonates segment is expected to be the largest segment in terms of revenue, throughout the forecast period.
The report’s geographical analysis suggests that Asia Pacific will show the fastest growth rate in the given forecast period. North America, the dominant region in 2013, is expected to continue leading the market for the time being, owing to significantly higher patient numbers.
Two prominent players in the global osteoporosis drugs market are Merck, Inc. and Novartis International AG, while the three dominant players are Pfizer, Inc., Amgen, Inc., and Eli Lilly and Company.

Monday, 27 June 2016

Tuberculosis Testing Market Set to Expand by 2020

A considerable portion of the population across geographies are suffering from a wide range of infectious diseases such as influenza, tuberculosis, AIDS, and several other bacterial and viral diseases. Tuberculosis or TB is one of the leading causes of death worldwide. Currently, organizations such as the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) have contributed largely towards improving global awareness regarding TB, its diagnosis, and available treatment options through TB control programs such as Stop TB. According to the WHO, in 2013, there were around 9 million new TB cases and close to 1.5 million TB deaths worldwide.
The global tuberculosis testing market has been categorized into seven segments based on major TB test types - smear microscopy, culture based tests, nucleic acid testing, Mantoux test, radiography (chest x-ray), drug susceptibility testing, and other tests such as serological tests, Interferon-Gamma Release Assays (IGRA), phage based tests, antigen-based tests, antibody-based tests, etc. Among such TB testing procedures available, culture based tests was the largest contributor in the global TB testing market. Culture based TB tests include both solid as well as liquid culture tests that have been most widely accepted due to their relatively high specificity and accuracy than other TB tests available in the global market. However, other TB tests segment that includes IGRA, serological tests, and others is expected to register fastest growth during the forecast period from 2014 to 2020 due to many advantages such as fast result generation, high accuracy, requirement of single visit ,etc
The global tuberculosis testing market was valued at USD 1,936.1 million in 2013 and is expected to reach USD 2,619.4 million by 2020, growing at a CAGR of 4.3% from 2014 to 2020. Some of the major driving factors facilitating the growth of this market are increasing incidences of tuberculosis and the rising acceptance of new, innovative, and advanced molecular and rapid culture diagnostic tests worldwide. In addition, increased involvement of some of the world’s leading non-profit healthcare organizations for the development of new TB diagnostic tests would further boost the growth this market. Moreover, the TB diagnostics market is observed to be a propelling as many new product developers and manufacturers are expected to venture into the market with a robust pipeline of testing technologies.
Asia Pacific dominated the global tuberculosis testing market in 2013 followed by North America. Key factor responsible for Asia Pacific dominating the global TB testing market is the presence of a vast patient pool, which is growing at a rapid pace due to very high incidence rate of the disease, especially in some of the emerging economies of the region, such as India and China. In contrast, North America has a relatively smaller patient pool with lower disease incidences. However, higher awareness, well developed healthcare infrastructure, rapid acceptance of improved but expensive TB tests and better purchasing power are contributing towards the second highest market share of North America.
Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche, Ltd., Hain Lifescience GmbH, bioMérieux SA, Hologic, Inc. QIAGEN, Akonni Biosystems, Inc., Abbott Laboratories, Alere, Inc., Cepheid, Epistem, Plc. and Sanofi are some of the major players operating in the global tuberculosis testing market. Among these, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc, F. Hoffmann-La Roche Ltd. and Hain Lifescience GmbH are the leading players in this market aspiring to introduce novel TB testing technologies in the global market.

Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market

There are a few key causes of a fatty liver, one of which is non-alcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance. Obesity is another factor that can significantly increase the chances of contracting NAFLD. According to the National Health and Nutrition Examination Survey, the rate of NAFLD in the U.S. within 2011 and 2012 was nearly 30%. In cases where NAFLD was not detected in time and reached higher levels of complications, non-alcoholic steatohepatitis (NASH) can occur. It is the most extreme form of non-alcoholic fatty liver disease and is a direct causative factor for liver cirrhosis. NAFLD by itself can be treated successfully if detected in time. NASH, on the other hand, needs special care.
The global non-alcoholic steatohepatitis therapeutics market is expected to reach US$20.2 bn by the end of 2025. It is expanding at a CAGR of 10.70% between 2015 and 2025. The key players in this market that are expected to play a major role in the market’s immediate future include Tobira Therapeutics, Inc., Conatus Pharmaceuticals, Immuron Ltd., Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and Astazeneca Plc.
Elafibranor Propels Global NASH Market
The major segments of the market by drug type include Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and potential drug candidates in phase III. Elafibranor is expected to lead the market in the near future by being the largest and fastest growing segment of the global non-alcoholic steatohepatitis therapeutics market. Elafibranor is currently the most advanced and most effective drug in this market and is expected to exhibit the highest CAGR of all the various drug types.
There are no treatments that are specifically used for non-alcoholic steatohepatitis. Apart from the various drugs used for the treatment of fatty liver, doctors often suggest the patient to start losing weight if they are overweight. Other suggestions given include completely avoiding alcohol, consuming a balanced diet, and increasing physical activity.
NASH and NAFLD Linked to Obesity
Medical records are pointing to an increasing prevalence of NAFLD and NASH across the world. However, these issues are more common in developed economies such as North America. This is due to the larger percentage of the obese population in the total population in developed regions than others. The global non-alcoholic steatohepatitis therapeutics market is, therefore, developing at a higher rate in countries such as the U.S., owing to the higher demand for NASH and NAFLD treatment options. The healthcare industry in these regions is taking fatty liver complications a lot more seriously. In the recent past, the number of obese adults and children in the U.S. have doubled and tripled, respectively. This is a major issue, as obese patients who suffer from NFALD or NASH are also likely to suffer from high blood cholesterol and diabetes.
Apart from obesity, patients of glucose intolerance and dyslipidemia are also prone to suffer from NFALD and NASH. There is no clear link that points to the reason NFALD occurs, but it is currently suggested that insulin resistance has a major role to play in it. In spite of the severity of the disease, patients are largely asymptomatic until complications arise. Therefore, the best preventive measure against NFALD and NASH is to lead a healthy life and moderate alcohol consumption.

U.S. Pregnancy Products Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2015 - 2023

Pregnancy presents several health-related challenges, for both the expecting mother and the baby. These challenges include diet to follow, medicines to take, and handling the several changes the body goes through. Skin care is another major challenge during pregnancy and the postpartum period. The ingredients in skin care products used during pregnancy are absorbed by the body. Therefore, pregnant women must use skin care products that are safe and do not cause any side effects. Several skin-related issues occur during pregnancy. These include stretch marks due to tearing of the dermis, especially in the third trimester, sagging skin that adds on layer of skin on thighs, tummy, waist, arms, and legs. Moreover, majority of women suffer from severe pain in body parts such as leg, hip, back, vagina, and thigh during pregnancy. Currently, several products are available in the market to overcome these skin-related issues during pregnancy and postpartum.
Based on type of product, the pregnancy products market in the U.S. has been classified into stretch mark minimizer, body restructuring gel, toning/firming lotion, itching prevention cream, nipple protection cream, breast cream, stressed leg product, and others. The others segment consists of moisturizing lotion, facial cream, dark spot treatments, etc. The stretch mark minimizer segment held the largest share of the pregnancy products market in the U.S. in 2014. The segment is likely to continue to dominate the market during the forecast period. However, the others segment is projected to expand at the highest growth rate from 2015 to 2023. Increase in the number of pregnant women in the U.S. and rise in distribution channels such as hypermarkets, supermarkets, retail stores, and online are likely to drive the pregnancy products market in the U.S. However, side effects associated with pregnancy products could hamper demand and limit the usage of pregnancy products.
Region-wise, the pregnancy products market in the U.S. has been segmented into Western United States, Southern United States, Northeastern United States, and the Central United States. Southern United States accounted for the largest share of the pregnancy products market in the U.S. in 2014. The region is likely to continue its dominance of the market during the forecast period due to high (total) fertility rate, rise in pregnancies, and increase in awareness among the female population. However, the pregnancy products market in Northeastern United States is anticipated to witness the fastest growth rate from 2015 to 2023. Factors such as decline in unintended pregnancies among teenagers can hinder the growth of the pregnancy products market in the U.S.
Television advertisements, information brochures, newspapers, magazines, online, and other media have proved to be effective mediums to spread awareness among women about the treatment of skin-related and other issues during pregnancy and postpartum. This provides an opportunity for manufacturers in the pregnancy products market in the U.S.
Major players in the pregnancy products market in the U.S. are Clarins Group, Expanscience Laboratories, Inc. (Mustela), Mama Mio US, Inc. (Mio), Noodle & Boo, Novena Maternity, Nine Naturals, LLC, and E.T. Browne Drug Co., Inc. (Palmers)

European Molecular Diagnostic Market witnesses a year of significant changes

According to a new market report published by Transparency Market Research “Molecular Diagnostic Market for Group A Streptococcus (GAS) Nucleic Acid (NA) Test Products Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023”, the Europe molecular diagnostic market for group A streptococcus (GAS) nucleic acid (NA) test products market was valued at US$ 8.3 Mn in 2014 and is projected to expand at a CAGR of 11.6% from 2015 to 2023 to reach US$ 22.3 Mn in 2023.
Rapid and accurate diagnosis is a key factor for effective disease treatment. Increasing incidence of Streptococcus pyogenes infection in Europe, advancement of technology, and rising demand for point-of-care testing act as a high impact drivers of the market. Advancements in techniques such as isothermal nucleic acid amplification tests is likely to propel the market during the forecast period. The molecular diagnostic market for group A streptococcus (GAS) nucleic acid (NA) test in Europe has been segmented based on type of test technique, end-user, and region.
A study conducted by the American Society for Microbiology concluded that incidence rate of Streptococcus pyogenes is high in countries in Northern Europe. The incidence of the disease has increased at a steady rate in most of these countries of the market. The automated detection system offers a faster, more flexible, and cost-effective solution to clinicians. Advancement of technology is bringing testing services to point-of-care. Due to its high sensitivity and accuracy the tests are backs up all negative rapid antigen assays. The Advancements in nucleic acid testing technologies and their adoption in Europe would result in high growth adoption of the technology will primarily occur in the developed countries. Ineffectiveness and slow adoption are the major restraints of the market.
The polymerase chain reaction segment held the largest share of the market in 2014, followed by the non-amplified tests segment. PCR is a traditional technology used for nucleic acid tests. However, the new, efficient, and user-friendly methods, such as isothermal nucleic acid amplification and non-amplified tests, are likely to capture higher market share in the near future. Isothermal nucleic acid amplification technology has been identified as the fastest growing segment during the forecast period due to its accuracy and rapid identification. Nucleic acid amplification techniques take tiny amounts of DNA or RNA, replicate them many times, and thus can detect minute traces of an organism in a specimen, avoiding the need for culture. Non-amplified technology using hybridization probe would capture a decent share in the market during the forecast period.
The hospitals end-user segment accounted for over 58.2% share of the nucleic acid (NA) test products market in Europe in terms of revenue in 2014, followed by the public health laboratories segment. Moreover, the segment is expected to gain market share and emerge as the fastest growing segment during the forecast period.
Western Europe was the largest market for nucleic acid (NA) test products in 2014, accounting for around 48.9% share. Western Europe dominated the market due to highly developed health care infrastructure and favorable reimbursement scenario. On the other hand, Northern Europe is expected to gain high market share during the forecast period owing to increase in incidence of Streptococcus pyogenes infection and high adoption rate.
Alere, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Meridian Bioscience, Inc., Nanosphere, Inc., and Quidel Corporation are the major players operating in European Molecular Diagnostic Market for Group A Streptococcus (GAS) Nucleic Acid (NA) Test Products market.

Leading Players in India Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market

Transparency Market Research has published a new report on the India sterilizers and surgical, dental care, and equipment disinfectors market. The sterilizers and surgical, dental care, and equipment disinfectors market in India is predicted to grow at an 8.20% CAGR from 2014 to 2020. The report, titled ‘Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market - India Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,’ states that the market will grow from INR 806.0 cr in 2013 to INR 1,390.2 cr by 2020. The rise in the disposable income of people and the increasing rate of hospital acquired infections (HAIs) are predicted to benefit the sterilizers and surgical, dental care, and equipment disinfectors market in India.
Sterilization destroys fungal and bacterial microorganisms through the use of chemical and physical agents. Chemical disinfectors and sterilizers are used to purify the devices used for dental procedures and surgeries. The rising unhealthy eating habits have led to a growing number of people undergoing dental procedures. This has benefited the demand for dental care equipment. The number of accidental injuries in India is increasing every year. This has led to the growth in the demand for surgical equipment, thus expected to propel the market.
In India, over the past few years, a high rate of hospital-acquired infections is being observed. This has made it mandatory for hospitals to use sterilized surgical equipment. The rising number of surgeries performed in private clinics and hospitals is predicted to benefit the sterilizers and surgical, dental care and equipment disinfectors market in India.
Currently, leading players in this market are focusing on introducing highly-advanced sterilizers and disinfectors in the Indian market. Companies such as Advanced Sterilization Products Services, Inc., Ipca Laboratories Ltd., PSK Pharma Private Limited, Ranbaxy Laboratories Ltd., Sanosil Biotech Pvt. Ltd., UPS Hygienes Pvt. Ltd., and Zep Superior Solutions are operating in this market. These companies are focusing on serving end users such as hospitals and nursing staff, equipment and devices used during surgeries, patients and caregivers, operating rooms, ICUs, and nursing tables, and others. Owing to the rising number of accidents, the operating rooms, ICUs, and nursing tables segment currently dominates the sterilizers and surgical, dental care, and equipment disinfectors market in India.
The sterilizers and surgical, dental care, and equipment disinfectors market in India is segmented on the basis of end user, surgery stage, application, and chemical formulation. Based on application, the market is classified into veterinary care centers and hospitals.
Ethyl-hexadecyl-dimethyl ammonium formulations, benzalkonium chloride formulations, alcohol-based agents, octenidine hydrochloride formulations, and povidone-iodine formulations are some of the chemical formulations of sterilizers and disinfectors.
Even though the growing number of surgeries will benefit the sterilizers and surgical, dental care, and equipment disinfectors market in India, it is predicted to be hampered by the rising use of disposable medical equipment and the carelessness in sterilization measures in the global healthcare sector. Decontamination and hand hygiene are at times ignored in many rural hospitals, making this another challenging factor for the market.
Key Segments of Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market in India.

Friday, 24 June 2016

Kidney Fibrosis Treatment Market - Strategy and innovation

Fibrosis is a process, which includes the formation of excess fibrous connective tissue in body tissues or organs in a repetitive manner. Kidney fibrosis is the major biological process causal for the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD). Kidney fibrosis is an unavoidable outcome of excessive formation of extracellular matrix, which occurs due to every type of CKD. Currently, the kidney fibrosis treatment market is a highly attractive commercial segment owing to the increasing base of patients suffering from various types CKD and renal fibrosis.
Some of the commercially available medications used for the treatment of kidney fibrosis disease are as follows:
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers (ARBs)
  • Renin inhibitors
  • Pirfenidone
  • Vasopeptidase inhibitors
It has been observed that any disease, which leads to chronic kidney disorder, might result in renal fibrosis. In terms of geography, North America is the largest market for kidney fibrosis treatment due to the large base of patients suffering from chronic kidney disease (CKD). According to the Centers for Disease Control and Prevention (CDC), in 2014, more than 20 million people in the U.S., are suffering from chronic kidney disease of varying severity levels. The organization also states that, in 2011, approximately 113,136 people in the U.S. started taking treatment for end-stage renal disease (ESRD).
Thus, this increasing base of kidney disease patients is expected to boosts the sales of kidney fibrosis treatment products. However, other regions such as South East Asia, Middle East and Latin America are some of the potential market where introduction of effective novel therapies might boosts up the overall market growth of kidney fibrosis treatment. Due to the consistent gradient of health concerns and rising awareness among population, these regions are expected to be the lucrative market venture for kidney fibrosis treatment.
Some of the major factors driving the growth of this market are increasing base of population suffering from chronic kidney diseases and high incidence rate of renal fibrosis among population. Moreover, development of safe and effective therapeutics for the treatment of kidney fibrosis is contributing to the growth of this market. For instance, in March 2014, a California based biopharmaceutical company, La Jolla Pharmaceutical Company, relieved positive results from phase II clinical trial of their proprietary GSC-100 drug molecule in chronic kidney disease (CKD). GSC-100 is a complex polysaccharide with a high molecular weight that inhibits the production of galectin-3, a molecule responsible for scarring or tissue fibrosis. Thus, the introduction of promising drugs in this market is likely to boosts the overall kidney fibrosis treatment market due to the high success and effectiveness rate of these potential molecules. Furthermore, increasing government support for developing novel therapies along with high research and development initiatives on the development of personalized medicines are also expected to fuel the growth of this market.
In addition, technological breakthrough such as point-of-care drug delivery systems and increased focus on retaining superior quality of life are some of the factors that might contribute in the growth of this market. However, rise in overall healthcare expenditure and stringent regulatory approvals are some of the market-restraining factors that might hinder the growth of the kidney fibrosis treatment market in future.
At present, the kidney fibrosis treatment market is a highly lucrative and promising market due to the increasing base of population suffering from chronic kidney diseases and renal fibrosis. Various pharmaceutical and biotechnology are trying to develop novel therapeutics, which can be used for the treatment of this disorder. Some of the companies involved with the development and commercialization of therapeutic products for the treatment of kidney fibrosis are F. Hoffmann-La Roche Ltd., Galectin Therapeutics, Inc., InterMune, Inc., La Jolla Pharmaceutical Company, Merck & Co. and Pfizer, Inc., amongst others.

Alternative Healthcare Providers Market Trends & Forecast up to 2023

Complementary or Alternative medicine(CAM) refers to different medical therapies and systems outside of conventional healthcare to improve and treat the mental and physical illness.CAM therapies are based on the knowledge, practices and skills derived from theories, experiences and philosophies to improve and maintain health, as well as to diagnose, prevent, and treat various disorders. Alternative healthcare providers offer a variety of medical and healthcare systems, products and practices used by patients without medical supervision. CAM therapies are particularly used by people with chronic illnesses and pain, such as liver disease, diabetes, osteoporosis, and cancer. Alternative system of healthcare include Ayurveda, unani medicines, yoga, acupuncture, homeopathic medicines and others systems of healthcare.
Complementary or Alternative medicine can be categorized on the basis of
Intervention
  • Alternative medical systems
  • Mind-body interventions
  • Biologically based therapies
  • Physical manipulation
  • Energy therapies.
Types
  • Ayurveda
  • Yoga
  • Naturopathy
  • Homeopathy
  • Unani
  • Siddha
  • Acupressure
  • Acupuncture
  • Others
Now a days, people are evidently looking for more gentle and natural methods of healing and thus are increasingly supporting different types of CAM therapies within existing healthcare systems that will subsequently lead to the growth of alternative healthcare providers market. According to an article published by the EUROCAM, an association of European CAM organizations, currently, CAM is practiced by around 145,000 doctors trained in conventional medicine and a particular CAM modality. The rising awareness and interest of healthcare professionals in CAM therapies is expected to drive the market of alternative healthcare providers market. Moreover, the World Health Assembly, the supreme decision-making body of the World Health Organization WHO has urged its member states to integrate CAM and traditional medicine within national healthcare system. This would further boost the market for alternative healthcare providers.
The global alternative healthcare providers market is witnessing an admirable growth due to medical advancements, high number of research activities in this segment and increasing prevalence of chronic diseases. The increasing prevalence of different cancers in developed as well as developing countries has resulted in a significant growth in alternative healthcare providers market. According to WHO, 14.1 million new cases of cancer were observed and 8.2 million deaths occurred throughout the world in 2012. This significant rise in cancer incidence has driven the growth of CAM therapies. However, lack of awareness and unregulated market may hinder the growth of alternative healthcare providers market.
In terms of geography, alternative healthcare providers market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East. Among these regions, North accounts for the largest share of alternative healthcare providers market due to increasing awareness about various CAM therapies among people and rising prevalence of chronic disorders such as diabetes, hypertension and cancer. Europe accounts for the second largest market for alternative healthcare providers owing to high acceptability of various CAM therapies, rising incidence chronic diseases and high disposable income. However, Asia Pacific market is expected to witness positive growth due to high rate of development in healthcare industry, rising demand for herbal and natural medicines and growing medical tourism industry.
The global alternative healthcare providers market is highly fragmented due to the participation of mid-sized and small sized manufacturers. Some of the major players in alternative healthcare providers market includes Allen Labratories Ltd. Baidyanath Herbal, Dabur Limited, Hamdard Laboratories, Medisynth Ch. Pvt. Ltd., and SBL Homeopathy Medicines.

Global Regenerative Medicine Market to Reach US$6.5 bn by 2019, Propelled by Increasing Demand for Tissue Engineering and Stem Cell Therapy

Regenerative medicine is considered as an emerging field of medical science that aims to regenerate, repair or replace damaged tissue and organs. U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Regenerative medicine has wide areas of application such as cardiovascular, neurology, orthopedic and musculoskeletal diseases and disorders. Technological advancement in tissue engineering and stem cell therapy is expected to drive the global market for regenerative medicine (bone and joint). Moreover, growing prevalence of bone and joint disorder has also accounted for the market growth of the global regenerative medicine (bone and joint). However, factors such as stringent regulatory compliance, ethical issues pertaining to stem cell therapy and post implantation rejection are expected to hinder the global market growth during the forecast period. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019.
The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period.
In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019.
North America was the largest market for regenerative medicine bone and joint application in 2012, accounting for largest market share of the total regenerative medicine (bone and joint) market. The regenerative medicine market in North America witnessed significant growth due to increasing demand of bone and joint reconstructive surgeries. Moreover, favorable government initiatives have also supported the growth of the regenerative medicine bone and joint application market in this region. European market was the second largest of the global market in 2012. Rising geriatric population in European Union is one of the major market drivers in this region as the geriatric group is more prone to suffer from arthritis. Moreover, extensive support and funding provided by European government for regenerative medicine would further accentuate the market growth in this region.
Asia-Pacific was observed to be a promising market for regenerative medicine bone and joint application during the study period owing to the demand of bone graft substitute in this region. This region is considered as an emerging market and is estimated to grow at the highest CAGR from 2013 to 2019. Manufacturer of regenerative medicine bone and joint products are expanding their operation in Asian countries (India, China, Japan and South Korea) as these economies hold immense potential for regenerative medicine bone and joint application. For instance, in May 2013, Smith & Nephew acquired Sushrut Surgical Pvt. Ltd. an Indian medical technology company. Sushrut Surgicals product portfolio includes trauma implants and instruments, spine and limb salvage products. This acquisition would expand and enhance the product offerings of Smith & Nephew and would also assist in capturing lucrative market share in Asia-Pacific region. In terms of key players the global regenerative medicine bone and joint application market is highly fragmented that comprises of DePuy Synthes, Inc. (HEALOS Bone Graft), Medtronic, Inc. (INFUSE Bone Graft), Stryker Corporation (Vitoss Bone Graft Substitute) and Zimmer Holdings, Inc (CopiOs Bone Void Filler).

Global Stem Cells Market to Reach US$119.5 bn by 2018, Rising Awareness about Therapeutic Benefits Boosts Popularity

Transparency Market Research, in a report titled “Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”, states that the global stem cells market is projected to witness remarkable growth from 2012 to 2018, fueled by increasing government support, unmet medical needs, rising stem cell banking services, and growing medical tourism. Driven by these factors, the global stem cells market is anticipated to expand at a 24.20% CAGR during the forecast period, rising from a value of US$26.2 bn in 2013 to US$119.5 bn by 2018.
Rise in disposable income in emerging economies, the increasing prevalence of neurodegenerative disorders, development of the contract research industry, and replacement of animal tissue in drug discovery are also anticipated to contribute towards the overall growth of the stem cells market.By product, the stem cells market is categorized into adult stem cells, induced pluripotent stem cells, very small embryonic-like stem cells, human embryonic stem cells, and rat neural stem cells. Adult stem cells, which dominated the overall market in 2011, include mesenchymal stem cells, dental stem cells, neuronal stem cells, hematopoietic stem cells, and umbilical cord stem cells.
On the basis of technology, the stem cells market is segmented into stem cell acquisition, production, cryopreservation, and expansion and sub-culture. Stem cell acquisition is the largest as well as the most rapidly developing technological segment and includes bone marrow harvesting, umbilical cord blood, and apheresis. The segment of stem cell production includes cloning, isolation, in-vitro fertilization, and cell culture.
On the basis of application, the stem cells market is bifurcated into regenerative medicine and drug discovery and development. Regenerative medicine, which holds the larger share in the stem cells market, covers major disciplines such as orthopedics, hematology, wound care, diabetes, incontinence, neurology, oncology, cardiovascular and myocardial infarction, spinal cord injuries, and liver disorders.
Geographically, the global stem cells market is divided into Europe, Asia Pacific, North America, and Rest of the World. North America dominates the overall market, followed by Europe owing to increased prevalence of neurological and cardiac disorders, state initiatives and provision of grants from several organizations, development of innovative therapies, strong research activities, and effective marketing solutions. The Asia Pacific stem cells market is anticipated to witness impressive growth over the next two years thanks to rapidly growing contract research outsourcing and booming medical tourism.
The leading companies profiled in the stem cells market report are Osiris Therapeutics, Advanced Cell Technology, Cellartis AB, Bioheart, Cellular Engineering Technologies, Biotime Inc., Cytori Therapeutics Inc., Angel Biotechnology, Stemcelltechnologies Inc., California Stem Cell Inc., Brainstorm Cell Therapeutics, and Celgene Corporation Inc. These players are analyzed based on aspects such as company and financial overview, product portfolio, business strategies, and recent developments.
North America Leads Global Stem Cells Market, Asia Pacific to Register Fastest Growth
Regionally, the global stem cells market is segmented into Europe, Asia Pacific, North America, and Rest of the World. Of these regions, North America led the global stem cells market in 2011, holding a majority share in the global market. The region was followed by Europe, with a share of over 25% of global stem cells market the same year. High prevalence of neurological and cardiac diseases in the U.S, which, according to the Centers for Disease Control and Prevention, causes more than 50% of the total deaths in the country every year, is a significant factor contributing to the growth of the stem cells market in North America.
In the next couple of years, the stem cells market in Asia Pacific is expected to register a double-digit CAGR. The rapidly growing sector of medical tourism and increase in contract research outsourcing to the region are the factors likely to boost the stem cells market in Asia Pacific.

Thursday, 23 June 2016

Mice Model Market expected to reach USD 1.75 Billion in 2023

Mice model marketMice models have long been the backbone of fundamental and applied research in life sciences and continues to grow at a rapid rate. The mice model market has transformed since 2001, the year rodent genome was mapped. Mice models have a wide array of applications such as basic research, developing new therapeutic strategies for the treatment of human diseases, drug discovery and development research (such as target characterization, drug screening, and toxicity and safety evaluation), and preclinical studies of drug efficacy. Hundreds of mice models have been developed to study diseases such as cancer, Huntington’s, Parkinson’s, Duchenne and Becker muscular dystrophy, and amyotrophic lateral sclerosis (ALS). In the last 25 years, around 80% of discoveries in the biomedical research has been linked to research on mice.
The global mice model market was valued at USD 1,008.1 million in 2014 and is projected to reach USD 1,749.3 million in 2023, expanding at a CAGR of 6.4% from 2015 to 2023. Major factor boosting the growth of the market is the growing application of mice models not only in the field of basic research, but also in applied field of drug development and discovery. Development of mice models of human diseases has progressed rapidly in the past few years. Mice model has become indispensable in the evaluation of established and experimental treatment strategies, especially in cancer, cardiovascular diseases, metabolic anomalies, and neurological disorders. Mice model applications in drug discovery include development of new therapeutic strategies for the treatment of human diseases, target identification and validation, drug screening and lead optimization, and toxicity and safety screening. Furthermore, advancements in genetic engineering assisting in evaluating drug mechanism of action and its responses are expected to impact the growth of the drug discovery market. On the other hand, factors such as stringent regulatory framework that require precise control on use of animals in laboratories, rising concern on animal cruelty, and ethical concerns over the use of animals could negatively impact market growth.
The mice model market has been segmented into three major categories: model type, specialty, and services. Based on model type, inbred was the largest segment of the global mice model market in 2014 due to advantages such as cost effectiveness and data reproducibility. Metabolic & regulatory diseases was the largest specialty segment of the mice model market in terms of revenue in 2014. The segment accounted for 29.6% share of the market in 2014. The mice model services market is anticipated to expand at a CAGR of 7.3% from 2015 to 2023. The cryopreservation and cryorecovery services segment would expand at the highest growth rate during the forecast period as it requires less investment to maintain mice strain for a longer time.
Based on geography, the mice model market has been segmented into North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World (RoW). North America was the largest market for mice model in 2014. Ongoing robust research activities for the development of drugs and biologics and presence of major pharmaceutical and biotechnology companies in the region are some of the factors responsible for the dominance of the region. Europe held the second largest share of the global mice model market in terms of revenue in 2014. Asia Pacific is expected to be the fastest growing market for mice model during the forecast period from 2015 to 2023. This high growth is primarily due to improving economic condition in countries such as India and China, and increasing number of academic and research, and contract research organizations in Asia Pacific. Japan, China, Australia, and India are the major markets in Asia Pacific that offer immense opportunities to companies in the mice model market. Continuous increase in biomedical research expenditure in China and India are expected to play a key role in fueling the growth in these markets. The market in MENA, Rest of the World (RoW) and Latin America would also grow significantly due to increasing public and private investment in biomedical researches. In addition, factors such as improving health care infrastructure, rising awareness, and flexible regulatory requirements in the region are driving the mice model market.
Key players operating in the global mice model market include Charles River Laboratories, Crescendo Biologics Limited, Deltagen, Inc., genOway S.A., Harlan Laboratories, Inc., ImmunoGenes AG, Taconic Biosciences, Inc., Lexicon Pharmaceuticals, SAGE Labs, The Jackson Laboratory, and TransGenic, Inc.